nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—CYP3A7—Temsirolimus—kidney cancer	0.0877	0.128	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0877	0.128	CbGbCtD
Zaleplon—CYP3A5—Temsirolimus—kidney cancer	0.0658	0.0963	CbGbCtD
Zaleplon—CYP3A4—Everolimus—kidney cancer	0.038	0.0556	CbGbCtD
Zaleplon—CYP3A7—Paclitaxel—kidney cancer	0.0301	0.0441	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0301	0.0441	CbGbCtD
Zaleplon—CYP3A7—Sorafenib—kidney cancer	0.0267	0.0391	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0267	0.0391	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.026	0.038	CbGbCtD
Zaleplon—CYP3A7—Vincristine—kidney cancer	0.026	0.038	CbGbCtD
Zaleplon—CYP3A4—Temsirolimus—kidney cancer	0.0257	0.0376	CbGbCtD
Zaleplon—CYP3A5—Erlotinib—kidney cancer	0.0247	0.0361	CbGbCtD
Zaleplon—CYP3A5—Paclitaxel—kidney cancer	0.0226	0.033	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.0217	0.0317	CbGbCtD
Zaleplon—CYP3A7—Sunitinib—kidney cancer	0.0217	0.0317	CbGbCtD
Zaleplon—CYP3A5—Sorafenib—kidney cancer	0.0201	0.0294	CbGbCtD
Zaleplon—CYP3A5—Vincristine—kidney cancer	0.0195	0.0285	CbGbCtD
Zaleplon—CYP3A5—Sunitinib—kidney cancer	0.0163	0.0238	CbGbCtD
Zaleplon—CYP3A4—Pazopanib—kidney cancer	0.0135	0.0197	CbGbCtD
Zaleplon—CYP3A4—Erlotinib—kidney cancer	0.00962	0.0141	CbGbCtD
Zaleplon—CYP3A4—Paclitaxel—kidney cancer	0.00881	0.0129	CbGbCtD
Zaleplon—CYP3A4—Sorafenib—kidney cancer	0.00782	0.0114	CbGbCtD
Zaleplon—CYP3A4—Vinblastine—kidney cancer	0.00772	0.0113	CbGbCtD
Zaleplon—CYP3A4—Vincristine—kidney cancer	0.00759	0.0111	CbGbCtD
Zaleplon—CYP3A4—Sunitinib—kidney cancer	0.00634	0.00927	CbGbCtD
Zaleplon—CYP3A4—Doxorubicin—kidney cancer	0.00475	0.00695	CbGbCtD
Zaleplon—CYP3A4—urine—kidney cancer	0.00151	0.0834	CbGeAlD
Zaleplon—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.0013	0.0723	CbGeAlD
Zaleplon—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.00112	0.0618	CbGeAlD
Zaleplon—AOX1—nephron tubule—kidney cancer	0.00102	0.0565	CbGeAlD
Zaleplon—AOX1—renal system—kidney cancer	0.000928	0.0514	CbGeAlD
Zaleplon—AOX1—kidney—kidney cancer	0.000897	0.0497	CbGeAlD
Zaleplon—AOX1—cortex of kidney—kidney cancer	0.000874	0.0484	CbGeAlD
Zaleplon—TSPO—nephron tubule—kidney cancer	0.000872	0.0483	CbGeAlD
Zaleplon—AOX1—gonad—kidney cancer	0.000832	0.0461	CbGeAlD
Zaleplon—AOX1—cardiac atrium—kidney cancer	0.000831	0.046	CbGeAlD
Zaleplon—GABRA2—cortex of kidney—kidney cancer	0.000806	0.0446	CbGeAlD
Zaleplon—TSPO—renal system—kidney cancer	0.000793	0.0439	CbGeAlD
Zaleplon—TSPO—kidney—kidney cancer	0.000766	0.0424	CbGeAlD
Zaleplon—TSPO—cortex of kidney—kidney cancer	0.000746	0.0413	CbGeAlD
Zaleplon—TSPO—gonad—kidney cancer	0.000711	0.0394	CbGeAlD
Zaleplon—TSPO—cardiac atrium—kidney cancer	0.00071	0.0393	CbGeAlD
Zaleplon—GABRB3—gonad—kidney cancer	0.000645	0.0357	CbGeAlD
Zaleplon—CYP3A5—nephron tubule—kidney cancer	0.00054	0.0299	CbGeAlD
Zaleplon—CYP3A5—renal system—kidney cancer	0.000491	0.0272	CbGeAlD
Zaleplon—CYP3A5—kidney—kidney cancer	0.000475	0.0263	CbGeAlD
Zaleplon—CYP3A5—cortex of kidney—kidney cancer	0.000462	0.0256	CbGeAlD
Zaleplon—CYP3A4—renal system—kidney cancer	0.000368	0.0204	CbGeAlD
Zaleplon—CYP3A4—kidney—kidney cancer	0.000356	0.0197	CbGeAlD
Zaleplon—Hypoglycaemia—Doxorubicin—kidney cancer	0.000116	0.000407	CcSEcCtD
Zaleplon—Vertigo—Paclitaxel—kidney cancer	0.000116	0.000406	CcSEcCtD
Zaleplon—Syncope—Paclitaxel—kidney cancer	0.000115	0.000406	CcSEcCtD
Zaleplon—Decreased appetite—Vincristine—kidney cancer	0.000115	0.000404	CcSEcCtD
Zaleplon—Pruritus—Sorafenib—kidney cancer	0.000115	0.000404	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000114	0.000402	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Vincristine—kidney cancer	0.000114	0.000401	CcSEcCtD
Zaleplon—Rash—Erlotinib—kidney cancer	0.000114	0.0004	CcSEcCtD
Zaleplon—Dermatitis—Erlotinib—kidney cancer	0.000114	0.0004	CcSEcCtD
Zaleplon—Palpitations—Paclitaxel—kidney cancer	0.000114	0.0004	CcSEcCtD
Zaleplon—Insomnia—Gemcitabine—kidney cancer	0.000113	0.000399	CcSEcCtD
Zaleplon—Eye disorder—Capecitabine—kidney cancer	0.000113	0.000399	CcSEcCtD
Zaleplon—Headache—Erlotinib—kidney cancer	0.000113	0.000398	CcSEcCtD
Zaleplon—Tinnitus—Capecitabine—kidney cancer	0.000113	0.000398	CcSEcCtD
Zaleplon—Loss of consciousness—Paclitaxel—kidney cancer	0.000113	0.000398	CcSEcCtD
Zaleplon—Pain—Vincristine—kidney cancer	0.000113	0.000398	CcSEcCtD
Zaleplon—Constipation—Vincristine—kidney cancer	0.000113	0.000398	CcSEcCtD
Zaleplon—Osteoarthritis—Doxorubicin—kidney cancer	0.000113	0.000397	CcSEcCtD
Zaleplon—Diplopia—Doxorubicin—kidney cancer	0.000113	0.000397	CcSEcCtD
Zaleplon—Paraesthesia—Gemcitabine—kidney cancer	0.000113	0.000396	CcSEcCtD
Zaleplon—Asthenia—Sunitinib—kidney cancer	0.000112	0.000394	CcSEcCtD
Zaleplon—Dyspnoea—Gemcitabine—kidney cancer	0.000112	0.000393	CcSEcCtD
Zaleplon—Nausea—Vinblastine—kidney cancer	0.000112	0.000392	CcSEcCtD
Zaleplon—Somnolence—Gemcitabine—kidney cancer	0.000111	0.000392	CcSEcCtD
Zaleplon—Affect lability—Doxorubicin—kidney cancer	0.000111	0.000391	CcSEcCtD
Zaleplon—Migraine—Doxorubicin—kidney cancer	0.000111	0.000391	CcSEcCtD
Zaleplon—Nausea—Everolimus—kidney cancer	0.000111	0.000391	CcSEcCtD
Zaleplon—Hypertension—Paclitaxel—kidney cancer	0.000111	0.000391	CcSEcCtD
Zaleplon—Pruritus—Sunitinib—kidney cancer	0.000111	0.000389	CcSEcCtD
Zaleplon—Immune system disorder—Capecitabine—kidney cancer	0.00011	0.000385	CcSEcCtD
Zaleplon—Arthralgia—Paclitaxel—kidney cancer	0.00011	0.000385	CcSEcCtD
Zaleplon—Chest pain—Paclitaxel—kidney cancer	0.00011	0.000385	CcSEcCtD
Zaleplon—Myalgia—Paclitaxel—kidney cancer	0.00011	0.000385	CcSEcCtD
Zaleplon—Anxiety—Paclitaxel—kidney cancer	0.000109	0.000384	CcSEcCtD
Zaleplon—Face oedema—Doxorubicin—kidney cancer	0.000109	0.000384	CcSEcCtD
Zaleplon—Decreased appetite—Gemcitabine—kidney cancer	0.000109	0.000383	CcSEcCtD
Zaleplon—Chills—Capecitabine—kidney cancer	0.000109	0.000383	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000109	0.000382	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000108	0.000381	CcSEcCtD
Zaleplon—Discomfort—Paclitaxel—kidney cancer	0.000108	0.000381	CcSEcCtD
Zaleplon—Gastrointestinal pain—Vincristine—kidney cancer	0.000108	0.00038	CcSEcCtD
Zaleplon—Dizziness—Sorafenib—kidney cancer	0.000107	0.000378	CcSEcCtD
Zaleplon—Constipation—Gemcitabine—kidney cancer	0.000107	0.000377	CcSEcCtD
Zaleplon—Pain—Gemcitabine—kidney cancer	0.000107	0.000377	CcSEcCtD
Zaleplon—Nausea—Erlotinib—kidney cancer	0.000107	0.000377	CcSEcCtD
Zaleplon—Alopecia—Capecitabine—kidney cancer	0.000107	0.000377	CcSEcCtD
Zaleplon—Dry mouth—Paclitaxel—kidney cancer	0.000107	0.000377	CcSEcCtD
Zaleplon—Mood swings—Doxorubicin—kidney cancer	0.000107	0.000376	CcSEcCtD
Zaleplon—Ataxia—Doxorubicin—kidney cancer	0.000106	0.000374	CcSEcCtD
Zaleplon—Mental disorder—Capecitabine—kidney cancer	0.000106	0.000374	CcSEcCtD
Zaleplon—Asthenia—Dactinomycin—kidney cancer	0.000106	0.000373	CcSEcCtD
Zaleplon—Confusional state—Paclitaxel—kidney cancer	0.000106	0.000372	CcSEcCtD
Zaleplon—Malnutrition—Capecitabine—kidney cancer	0.000106	0.000371	CcSEcCtD
Zaleplon—Anaphylactic shock—Paclitaxel—kidney cancer	0.000105	0.000369	CcSEcCtD
Zaleplon—Oedema—Paclitaxel—kidney cancer	0.000105	0.000369	CcSEcCtD
Zaleplon—Abdominal pain—Vincristine—kidney cancer	0.000104	0.000367	CcSEcCtD
Zaleplon—Body temperature increased—Vincristine—kidney cancer	0.000104	0.000367	CcSEcCtD
Zaleplon—Liver function test abnormal—Doxorubicin—kidney cancer	0.000104	0.000367	CcSEcCtD
Zaleplon—Flatulence—Capecitabine—kidney cancer	0.000104	0.000366	CcSEcCtD
Zaleplon—Dry skin—Doxorubicin—kidney cancer	0.000104	0.000364	CcSEcCtD
Zaleplon—Dysgeusia—Capecitabine—kidney cancer	0.000103	0.000364	CcSEcCtD
Zaleplon—Dizziness—Sunitinib—kidney cancer	0.000103	0.000363	CcSEcCtD
Zaleplon—Feeling abnormal—Gemcitabine—kidney cancer	0.000103	0.000363	CcSEcCtD
Zaleplon—Shock—Paclitaxel—kidney cancer	0.000103	0.000363	CcSEcCtD
Zaleplon—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000103	0.000363	CcSEcCtD
Zaleplon—Nervous system disorder—Paclitaxel—kidney cancer	0.000103	0.000362	CcSEcCtD
Zaleplon—Tachycardia—Paclitaxel—kidney cancer	0.000102	0.00036	CcSEcCtD
Zaleplon—Rash—Sorafenib—kidney cancer	0.000102	0.00036	CcSEcCtD
Zaleplon—Dermatitis—Sorafenib—kidney cancer	0.000102	0.00036	CcSEcCtD
Zaleplon—Back pain—Capecitabine—kidney cancer	0.000102	0.000359	CcSEcCtD
Zaleplon—Breast disorder—Doxorubicin—kidney cancer	0.000102	0.000359	CcSEcCtD
Zaleplon—Skin disorder—Paclitaxel—kidney cancer	0.000102	0.000359	CcSEcCtD
Zaleplon—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000102	0.000358	CcSEcCtD
Zaleplon—Headache—Sorafenib—kidney cancer	0.000102	0.000358	CcSEcCtD
Zaleplon—Hyperhidrosis—Paclitaxel—kidney cancer	0.000101	0.000357	CcSEcCtD
Zaleplon—Anorexia—Paclitaxel—kidney cancer	0.0001	0.000352	CcSEcCtD
Zaleplon—Gastritis—Doxorubicin—kidney cancer	0.0001	0.000352	CcSEcCtD
Zaleplon—Muscular weakness—Doxorubicin—kidney cancer	9.97e-05	0.00035	CcSEcCtD
Zaleplon—Alanine aminotransferase increased—Doxorubicin—kidney cancer	9.97e-05	0.00035	CcSEcCtD
Zaleplon—Body temperature increased—Gemcitabine—kidney cancer	9.91e-05	0.000349	CcSEcCtD
Zaleplon—Tremor—Capecitabine—kidney cancer	9.89e-05	0.000348	CcSEcCtD
Zaleplon—Rash—Sunitinib—kidney cancer	9.85e-05	0.000347	CcSEcCtD
Zaleplon—Dermatitis—Sunitinib—kidney cancer	9.84e-05	0.000346	CcSEcCtD
Zaleplon—Hypotension—Paclitaxel—kidney cancer	9.81e-05	0.000345	CcSEcCtD
Zaleplon—Ill-defined disorder—Capecitabine—kidney cancer	9.79e-05	0.000344	CcSEcCtD
Zaleplon—Headache—Sunitinib—kidney cancer	9.79e-05	0.000344	CcSEcCtD
Zaleplon—Asthma—Doxorubicin—kidney cancer	9.77e-05	0.000343	CcSEcCtD
Zaleplon—Dysphagia—Doxorubicin—kidney cancer	9.77e-05	0.000343	CcSEcCtD
Zaleplon—Anaemia—Capecitabine—kidney cancer	9.76e-05	0.000343	CcSEcCtD
Zaleplon—Eosinophilia—Doxorubicin—kidney cancer	9.67e-05	0.00034	CcSEcCtD
Zaleplon—Nausea—Sorafenib—kidney cancer	9.65e-05	0.000339	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Paclitaxel—kidney cancer	9.56e-05	0.000336	CcSEcCtD
Zaleplon—Malaise—Capecitabine—kidney cancer	9.52e-05	0.000335	CcSEcCtD
Zaleplon—Angina pectoris—Doxorubicin—kidney cancer	9.51e-05	0.000335	CcSEcCtD
Zaleplon—Insomnia—Paclitaxel—kidney cancer	9.5e-05	0.000334	CcSEcCtD
Zaleplon—Vertigo—Capecitabine—kidney cancer	9.48e-05	0.000334	CcSEcCtD
Zaleplon—Asthenia—Vincristine—kidney cancer	9.48e-05	0.000334	CcSEcCtD
Zaleplon—Syncope—Capecitabine—kidney cancer	9.47e-05	0.000333	CcSEcCtD
Zaleplon—Paraesthesia—Paclitaxel—kidney cancer	9.43e-05	0.000332	CcSEcCtD
Zaleplon—Bronchitis—Doxorubicin—kidney cancer	9.39e-05	0.00033	CcSEcCtD
Zaleplon—Dyspnoea—Paclitaxel—kidney cancer	9.36e-05	0.000329	CcSEcCtD
Zaleplon—Somnolence—Paclitaxel—kidney cancer	9.33e-05	0.000328	CcSEcCtD
Zaleplon—Palpitations—Capecitabine—kidney cancer	9.33e-05	0.000328	CcSEcCtD
Zaleplon—Rash—Dactinomycin—kidney cancer	9.33e-05	0.000328	CcSEcCtD
Zaleplon—Nausea—Sunitinib—kidney cancer	9.28e-05	0.000326	CcSEcCtD
Zaleplon—Loss of consciousness—Capecitabine—kidney cancer	9.28e-05	0.000326	CcSEcCtD
Zaleplon—Dyspepsia—Paclitaxel—kidney cancer	9.24e-05	0.000325	CcSEcCtD
Zaleplon—Dysuria—Doxorubicin—kidney cancer	9.13e-05	0.000321	CcSEcCtD
Zaleplon—Decreased appetite—Paclitaxel—kidney cancer	9.13e-05	0.000321	CcSEcCtD
Zaleplon—Hypertension—Capecitabine—kidney cancer	9.11e-05	0.000321	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.06e-05	0.000319	CcSEcCtD
Zaleplon—Pollakiuria—Doxorubicin—kidney cancer	9.02e-05	0.000317	CcSEcCtD
Zaleplon—Asthenia—Gemcitabine—kidney cancer	9e-05	0.000316	CcSEcCtD
Zaleplon—Chest pain—Capecitabine—kidney cancer	8.99e-05	0.000316	CcSEcCtD
Zaleplon—Myalgia—Capecitabine—kidney cancer	8.99e-05	0.000316	CcSEcCtD
Zaleplon—Arthralgia—Capecitabine—kidney cancer	8.99e-05	0.000316	CcSEcCtD
Zaleplon—Pain—Paclitaxel—kidney cancer	8.98e-05	0.000316	CcSEcCtD
Zaleplon—Constipation—Paclitaxel—kidney cancer	8.98e-05	0.000316	CcSEcCtD
Zaleplon—Anxiety—Capecitabine—kidney cancer	8.96e-05	0.000315	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	8.93e-05	0.000314	CcSEcCtD
Zaleplon—Photosensitivity reaction—Doxorubicin—kidney cancer	8.91e-05	0.000313	CcSEcCtD
Zaleplon—Weight increased—Doxorubicin—kidney cancer	8.89e-05	0.000313	CcSEcCtD
Zaleplon—Discomfort—Capecitabine—kidney cancer	8.88e-05	0.000312	CcSEcCtD
Zaleplon—Pruritus—Gemcitabine—kidney cancer	8.87e-05	0.000312	CcSEcCtD
Zaleplon—Weight decreased—Doxorubicin—kidney cancer	8.84e-05	0.000311	CcSEcCtD
Zaleplon—Hyperglycaemia—Doxorubicin—kidney cancer	8.81e-05	0.00031	CcSEcCtD
Zaleplon—Dry mouth—Capecitabine—kidney cancer	8.79e-05	0.000309	CcSEcCtD
Zaleplon—Nausea—Dactinomycin—kidney cancer	8.79e-05	0.000309	CcSEcCtD
Zaleplon—Pneumonia—Doxorubicin—kidney cancer	8.76e-05	0.000308	CcSEcCtD
Zaleplon—Dizziness—Vincristine—kidney cancer	8.74e-05	0.000307	CcSEcCtD
Zaleplon—Confusional state—Capecitabine—kidney cancer	8.69e-05	0.000306	CcSEcCtD
Zaleplon—Feeling abnormal—Paclitaxel—kidney cancer	8.65e-05	0.000304	CcSEcCtD
Zaleplon—Oedema—Capecitabine—kidney cancer	8.62e-05	0.000303	CcSEcCtD
Zaleplon—Gastrointestinal pain—Paclitaxel—kidney cancer	8.58e-05	0.000302	CcSEcCtD
Zaleplon—Neuropathy peripheral—Doxorubicin—kidney cancer	8.54e-05	0.0003	CcSEcCtD
Zaleplon—Stomatitis—Doxorubicin—kidney cancer	8.49e-05	0.000298	CcSEcCtD
Zaleplon—Shock—Capecitabine—kidney cancer	8.48e-05	0.000298	CcSEcCtD
Zaleplon—Conjunctivitis—Doxorubicin—kidney cancer	8.46e-05	0.000298	CcSEcCtD
Zaleplon—Nervous system disorder—Capecitabine—kidney cancer	8.45e-05	0.000297	CcSEcCtD
Zaleplon—Tachycardia—Capecitabine—kidney cancer	8.41e-05	0.000296	CcSEcCtD
Zaleplon—Skin disorder—Capecitabine—kidney cancer	8.37e-05	0.000294	CcSEcCtD
Zaleplon—Sweating—Doxorubicin—kidney cancer	8.35e-05	0.000294	CcSEcCtD
Zaleplon—Urticaria—Paclitaxel—kidney cancer	8.34e-05	0.000293	CcSEcCtD
Zaleplon—Rash—Vincristine—kidney cancer	8.33e-05	0.000293	CcSEcCtD
Zaleplon—Hyperhidrosis—Capecitabine—kidney cancer	8.33e-05	0.000293	CcSEcCtD
Zaleplon—Dermatitis—Vincristine—kidney cancer	8.33e-05	0.000293	CcSEcCtD
Zaleplon—Haematuria—Doxorubicin—kidney cancer	8.3e-05	0.000292	CcSEcCtD
Zaleplon—Abdominal pain—Paclitaxel—kidney cancer	8.3e-05	0.000292	CcSEcCtD
Zaleplon—Body temperature increased—Paclitaxel—kidney cancer	8.3e-05	0.000292	CcSEcCtD
Zaleplon—Headache—Vincristine—kidney cancer	8.28e-05	0.000291	CcSEcCtD
Zaleplon—Hepatobiliary disease—Doxorubicin—kidney cancer	8.24e-05	0.00029	CcSEcCtD
Zaleplon—Epistaxis—Doxorubicin—kidney cancer	8.21e-05	0.000289	CcSEcCtD
Zaleplon—Anorexia—Capecitabine—kidney cancer	8.21e-05	0.000289	CcSEcCtD
Zaleplon—Hypotension—Capecitabine—kidney cancer	8.05e-05	0.000283	CcSEcCtD
Zaleplon—Rash—Gemcitabine—kidney cancer	7.91e-05	0.000278	CcSEcCtD
Zaleplon—Dermatitis—Gemcitabine—kidney cancer	7.9e-05	0.000278	CcSEcCtD
Zaleplon—Headache—Gemcitabine—kidney cancer	7.86e-05	0.000276	CcSEcCtD
Zaleplon—Nausea—Vincristine—kidney cancer	7.85e-05	0.000276	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Capecitabine—kidney cancer	7.85e-05	0.000276	CcSEcCtD
Zaleplon—Insomnia—Capecitabine—kidney cancer	7.79e-05	0.000274	CcSEcCtD
Zaleplon—Hypoaesthesia—Doxorubicin—kidney cancer	7.78e-05	0.000274	CcSEcCtD
Zaleplon—Paraesthesia—Capecitabine—kidney cancer	7.74e-05	0.000272	CcSEcCtD
Zaleplon—Oedema peripheral—Doxorubicin—kidney cancer	7.7e-05	0.000271	CcSEcCtD
Zaleplon—Dyspnoea—Capecitabine—kidney cancer	7.68e-05	0.00027	CcSEcCtD
Zaleplon—Dyspepsia—Capecitabine—kidney cancer	7.58e-05	0.000267	CcSEcCtD
Zaleplon—Visual impairment—Doxorubicin—kidney cancer	7.53e-05	0.000265	CcSEcCtD
Zaleplon—Asthenia—Paclitaxel—kidney cancer	7.53e-05	0.000265	CcSEcCtD
Zaleplon—Decreased appetite—Capecitabine—kidney cancer	7.49e-05	0.000263	CcSEcCtD
Zaleplon—Nausea—Gemcitabine—kidney cancer	7.45e-05	0.000262	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Capecitabine—kidney cancer	7.44e-05	0.000262	CcSEcCtD
Zaleplon—Pruritus—Paclitaxel—kidney cancer	7.43e-05	0.000261	CcSEcCtD
Zaleplon—Constipation—Capecitabine—kidney cancer	7.37e-05	0.000259	CcSEcCtD
Zaleplon—Pain—Capecitabine—kidney cancer	7.37e-05	0.000259	CcSEcCtD
Zaleplon—Eye disorder—Doxorubicin—kidney cancer	7.3e-05	0.000257	CcSEcCtD
Zaleplon—Tinnitus—Doxorubicin—kidney cancer	7.29e-05	0.000256	CcSEcCtD
Zaleplon—Feeling abnormal—Capecitabine—kidney cancer	7.1e-05	0.00025	CcSEcCtD
Zaleplon—Immune system disorder—Doxorubicin—kidney cancer	7.06e-05	0.000248	CcSEcCtD
Zaleplon—Gastrointestinal pain—Capecitabine—kidney cancer	7.04e-05	0.000248	CcSEcCtD
Zaleplon—Chills—Doxorubicin—kidney cancer	7.01e-05	0.000247	CcSEcCtD
Zaleplon—Dizziness—Paclitaxel—kidney cancer	6.94e-05	0.000244	CcSEcCtD
Zaleplon—Alopecia—Doxorubicin—kidney cancer	6.91e-05	0.000243	CcSEcCtD
Zaleplon—Mental disorder—Doxorubicin—kidney cancer	6.85e-05	0.000241	CcSEcCtD
Zaleplon—Urticaria—Capecitabine—kidney cancer	6.84e-05	0.000241	CcSEcCtD
Zaleplon—Abdominal pain—Capecitabine—kidney cancer	6.81e-05	0.00024	CcSEcCtD
Zaleplon—Body temperature increased—Capecitabine—kidney cancer	6.81e-05	0.00024	CcSEcCtD
Zaleplon—Malnutrition—Doxorubicin—kidney cancer	6.8e-05	0.000239	CcSEcCtD
Zaleplon—Flatulence—Doxorubicin—kidney cancer	6.71e-05	0.000236	CcSEcCtD
Zaleplon—Tension—Doxorubicin—kidney cancer	6.68e-05	0.000235	CcSEcCtD
Zaleplon—Dysgeusia—Doxorubicin—kidney cancer	6.66e-05	0.000234	CcSEcCtD
Zaleplon—Rash—Paclitaxel—kidney cancer	6.62e-05	0.000233	CcSEcCtD
Zaleplon—Dermatitis—Paclitaxel—kidney cancer	6.61e-05	0.000233	CcSEcCtD
Zaleplon—Nervousness—Doxorubicin—kidney cancer	6.61e-05	0.000232	CcSEcCtD
Zaleplon—Back pain—Doxorubicin—kidney cancer	6.58e-05	0.000231	CcSEcCtD
Zaleplon—Headache—Paclitaxel—kidney cancer	6.58e-05	0.000231	CcSEcCtD
Zaleplon—Ill-defined disorder—Doxorubicin—kidney cancer	6.31e-05	0.000222	CcSEcCtD
Zaleplon—Anaemia—Doxorubicin—kidney cancer	6.29e-05	0.000221	CcSEcCtD
Zaleplon—Agitation—Doxorubicin—kidney cancer	6.25e-05	0.00022	CcSEcCtD
Zaleplon—Nausea—Paclitaxel—kidney cancer	6.24e-05	0.000219	CcSEcCtD
Zaleplon—Asthenia—Capecitabine—kidney cancer	6.18e-05	0.000217	CcSEcCtD
Zaleplon—Malaise—Doxorubicin—kidney cancer	6.14e-05	0.000216	CcSEcCtD
Zaleplon—Vertigo—Doxorubicin—kidney cancer	6.11e-05	0.000215	CcSEcCtD
Zaleplon—Syncope—Doxorubicin—kidney cancer	6.1e-05	0.000215	CcSEcCtD
Zaleplon—Pruritus—Capecitabine—kidney cancer	6.1e-05	0.000214	CcSEcCtD
Zaleplon—Palpitations—Doxorubicin—kidney cancer	6.01e-05	0.000211	CcSEcCtD
Zaleplon—Loss of consciousness—Doxorubicin—kidney cancer	5.98e-05	0.00021	CcSEcCtD
Zaleplon—Hypertension—Doxorubicin—kidney cancer	5.87e-05	0.000207	CcSEcCtD
Zaleplon—Chest pain—Doxorubicin—kidney cancer	5.79e-05	0.000204	CcSEcCtD
Zaleplon—Arthralgia—Doxorubicin—kidney cancer	5.79e-05	0.000204	CcSEcCtD
Zaleplon—Myalgia—Doxorubicin—kidney cancer	5.79e-05	0.000204	CcSEcCtD
Zaleplon—Anxiety—Doxorubicin—kidney cancer	5.77e-05	0.000203	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.75e-05	0.000202	CcSEcCtD
Zaleplon—Discomfort—Doxorubicin—kidney cancer	5.72e-05	0.000201	CcSEcCtD
Zaleplon—Dizziness—Capecitabine—kidney cancer	5.7e-05	0.0002	CcSEcCtD
Zaleplon—Dry mouth—Doxorubicin—kidney cancer	5.67e-05	0.000199	CcSEcCtD
Zaleplon—Confusional state—Doxorubicin—kidney cancer	5.6e-05	0.000197	CcSEcCtD
Zaleplon—Oedema—Doxorubicin—kidney cancer	5.55e-05	0.000195	CcSEcCtD
Zaleplon—Anaphylactic shock—Doxorubicin—kidney cancer	5.55e-05	0.000195	CcSEcCtD
Zaleplon—Shock—Doxorubicin—kidney cancer	5.46e-05	0.000192	CcSEcCtD
Zaleplon—Nervous system disorder—Doxorubicin—kidney cancer	5.45e-05	0.000192	CcSEcCtD
Zaleplon—Rash—Capecitabine—kidney cancer	5.43e-05	0.000191	CcSEcCtD
Zaleplon—Dermatitis—Capecitabine—kidney cancer	5.43e-05	0.000191	CcSEcCtD
Zaleplon—Tachycardia—Doxorubicin—kidney cancer	5.42e-05	0.000191	CcSEcCtD
Zaleplon—Headache—Capecitabine—kidney cancer	5.4e-05	0.00019	CcSEcCtD
Zaleplon—Skin disorder—Doxorubicin—kidney cancer	5.39e-05	0.00019	CcSEcCtD
Zaleplon—Hyperhidrosis—Doxorubicin—kidney cancer	5.37e-05	0.000189	CcSEcCtD
Zaleplon—Anorexia—Doxorubicin—kidney cancer	5.29e-05	0.000186	CcSEcCtD
Zaleplon—Hypotension—Doxorubicin—kidney cancer	5.19e-05	0.000182	CcSEcCtD
Zaleplon—Nausea—Capecitabine—kidney cancer	5.12e-05	0.00018	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Doxorubicin—kidney cancer	5.06e-05	0.000178	CcSEcCtD
Zaleplon—Insomnia—Doxorubicin—kidney cancer	5.02e-05	0.000177	CcSEcCtD
Zaleplon—Paraesthesia—Doxorubicin—kidney cancer	4.99e-05	0.000175	CcSEcCtD
Zaleplon—Dyspnoea—Doxorubicin—kidney cancer	4.95e-05	0.000174	CcSEcCtD
Zaleplon—Somnolence—Doxorubicin—kidney cancer	4.94e-05	0.000174	CcSEcCtD
Zaleplon—Dyspepsia—Doxorubicin—kidney cancer	4.89e-05	0.000172	CcSEcCtD
Zaleplon—Decreased appetite—Doxorubicin—kidney cancer	4.83e-05	0.00017	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.79e-05	0.000169	CcSEcCtD
Zaleplon—Pain—Doxorubicin—kidney cancer	4.75e-05	0.000167	CcSEcCtD
Zaleplon—Constipation—Doxorubicin—kidney cancer	4.75e-05	0.000167	CcSEcCtD
Zaleplon—Feeling abnormal—Doxorubicin—kidney cancer	4.58e-05	0.000161	CcSEcCtD
Zaleplon—Gastrointestinal pain—Doxorubicin—kidney cancer	4.54e-05	0.00016	CcSEcCtD
Zaleplon—Urticaria—Doxorubicin—kidney cancer	4.41e-05	0.000155	CcSEcCtD
Zaleplon—Abdominal pain—Doxorubicin—kidney cancer	4.39e-05	0.000154	CcSEcCtD
Zaleplon—Body temperature increased—Doxorubicin—kidney cancer	4.39e-05	0.000154	CcSEcCtD
Zaleplon—Asthenia—Doxorubicin—kidney cancer	3.98e-05	0.00014	CcSEcCtD
Zaleplon—Pruritus—Doxorubicin—kidney cancer	3.93e-05	0.000138	CcSEcCtD
Zaleplon—Dizziness—Doxorubicin—kidney cancer	3.67e-05	0.000129	CcSEcCtD
Zaleplon—Rash—Doxorubicin—kidney cancer	3.5e-05	0.000123	CcSEcCtD
Zaleplon—Dermatitis—Doxorubicin—kidney cancer	3.5e-05	0.000123	CcSEcCtD
Zaleplon—Headache—Doxorubicin—kidney cancer	3.48e-05	0.000122	CcSEcCtD
Zaleplon—Nausea—Doxorubicin—kidney cancer	3.3e-05	0.000116	CcSEcCtD
Zaleplon—CYP3A5—Phase 1 - Functionalization of compounds—POMC—kidney cancer	2.9e-05	0.00203	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—LDHB—kidney cancer	2.88e-05	0.00202	CbGpPWpGaD
Zaleplon—CYP3A7—Biological oxidations—CYP1A1—kidney cancer	2.86e-05	0.002	CbGpPWpGaD
Zaleplon—CYP3A7—Metapathway biotransformation—CYP1A1—kidney cancer	2.82e-05	0.00197	CbGpPWpGaD
Zaleplon—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—kidney cancer	2.82e-05	0.00197	CbGpPWpGaD
Zaleplon—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	2.81e-05	0.00197	CbGpPWpGaD
Zaleplon—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	2.76e-05	0.00193	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	2.71e-05	0.0019	CbGpPWpGaD
Zaleplon—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—kidney cancer	2.7e-05	0.00189	CbGpPWpGaD
Zaleplon—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—kidney cancer	2.64e-05	0.00185	CbGpPWpGaD
Zaleplon—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—kidney cancer	2.63e-05	0.00184	CbGpPWpGaD
Zaleplon—AOX1—Disease—RPL14—kidney cancer	2.61e-05	0.00183	CbGpPWpGaD
Zaleplon—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—kidney cancer	2.58e-05	0.00181	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—RAF1—kidney cancer	2.57e-05	0.0018	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—RELA—kidney cancer	2.56e-05	0.00179	CbGpPWpGaD
Zaleplon—GABRB2—Transmission across Chemical Synapses—BRAF—kidney cancer	2.54e-05	0.00178	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ACY1—kidney cancer	2.51e-05	0.00176	CbGpPWpGaD
Zaleplon—GABRB2—Ion channel transport—RAF1—kidney cancer	2.51e-05	0.00176	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—MTOR—kidney cancer	2.51e-05	0.00176	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—CA9—kidney cancer	2.5e-05	0.00175	CbGpPWpGaD
Zaleplon—GABRA2—Transmission across Chemical Synapses—BRAF—kidney cancer	2.38e-05	0.00167	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—GSTP1—kidney cancer	2.37e-05	0.00166	CbGpPWpGaD
Zaleplon—GABRB3—Transmission across Chemical Synapses—BRAF—kidney cancer	2.36e-05	0.00166	CbGpPWpGaD
Zaleplon—AOX1—Disease—ITPR2—kidney cancer	2.36e-05	0.00165	CbGpPWpGaD
Zaleplon—GABRA2—Ion channel transport—RAF1—kidney cancer	2.35e-05	0.00165	CbGpPWpGaD
Zaleplon—CYP3A5—Metapathway biotransformation—GSTP1—kidney cancer	2.34e-05	0.00164	CbGpPWpGaD
Zaleplon—GABRB3—Ion channel transport—RAF1—kidney cancer	2.34e-05	0.00164	CbGpPWpGaD
Zaleplon—GABRG2—Transmission across Chemical Synapses—BRAF—kidney cancer	2.32e-05	0.00163	CbGpPWpGaD
Zaleplon—GABRG2—Ion channel transport—RAF1—kidney cancer	2.29e-05	0.00161	CbGpPWpGaD
Zaleplon—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—kidney cancer	2.25e-05	0.00158	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—JUN—kidney cancer	2.24e-05	0.00157	CbGpPWpGaD
Zaleplon—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	2.23e-05	0.00156	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—CTNNB1—kidney cancer	2.22e-05	0.00156	CbGpPWpGaD
Zaleplon—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	2.2e-05	0.00154	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—GSTM1—kidney cancer	2.18e-05	0.00153	CbGpPWpGaD
Zaleplon—CYP3A5—Metapathway biotransformation—GSTM1—kidney cancer	2.15e-05	0.00151	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PDHB—kidney cancer	2.14e-05	0.0015	CbGpPWpGaD
Zaleplon—CYP3A7—Biological oxidations—POMC—kidney cancer	2.13e-05	0.00149	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—CRABP1—kidney cancer	2.13e-05	0.00149	CbGpPWpGaD
Zaleplon—GABRB2—Transmission across Chemical Synapses—RAF1—kidney cancer	2.12e-05	0.00148	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—CYP1A1—kidney cancer	2.07e-05	0.00145	CbGpPWpGaD
Zaleplon—CYP3A5—Metapathway biotransformation—CYP1A1—kidney cancer	2.04e-05	0.00143	CbGpPWpGaD
Zaleplon—GABRA1—Transmission across Chemical Synapses—BRAF—kidney cancer	2.03e-05	0.00142	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.02e-05	0.00142	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—CCBL1—kidney cancer	2.01e-05	0.00141	CbGpPWpGaD
Zaleplon—GABRA1—Ion channel transport—RAF1—kidney cancer	2.01e-05	0.0014	CbGpPWpGaD
Zaleplon—GABRA2—Transmission across Chemical Synapses—RAF1—kidney cancer	1.99e-05	0.00139	CbGpPWpGaD
Zaleplon—AOX1—Disease—PSMD7—kidney cancer	1.98e-05	0.00139	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—ITPR2—kidney cancer	1.98e-05	0.00138	CbGpPWpGaD
Zaleplon—GABRB3—Transmission across Chemical Synapses—RAF1—kidney cancer	1.97e-05	0.00138	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.95e-05	0.00137	CbGpPWpGaD
Zaleplon—GABRB2—Neuronal System—BRAF—kidney cancer	1.94e-05	0.00136	CbGpPWpGaD
Zaleplon—GABRG2—Transmission across Chemical Synapses—RAF1—kidney cancer	1.94e-05	0.00136	CbGpPWpGaD
Zaleplon—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—kidney cancer	1.93e-05	0.00135	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.9e-05	0.00133	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.88e-05	0.00132	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.85e-05	0.0013	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—MAPK3—kidney cancer	1.85e-05	0.0013	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.83e-05	0.00128	CbGpPWpGaD
Zaleplon—GABRA2—Neuronal System—BRAF—kidney cancer	1.82e-05	0.00128	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.82e-05	0.00127	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ACY1—kidney cancer	1.82e-05	0.00127	CbGpPWpGaD
Zaleplon—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—kidney cancer	1.81e-05	0.00127	CbGpPWpGaD
Zaleplon—GABRB3—Neuronal System—BRAF—kidney cancer	1.81e-05	0.00127	CbGpPWpGaD
Zaleplon—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.81e-05	0.00127	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTT1—kidney cancer	1.8e-05	0.00126	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—ACHE—kidney cancer	1.8e-05	0.00126	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—JUN—kidney cancer	1.8e-05	0.00126	CbGpPWpGaD
Zaleplon—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—kidney cancer	1.8e-05	0.00126	CbGpPWpGaD
Zaleplon—AOX1—Disease—SLC2A1—kidney cancer	1.79e-05	0.00125	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	1.79e-05	0.00125	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.79e-05	0.00125	CbGpPWpGaD
Zaleplon—GABRG2—Neuronal System—BRAF—kidney cancer	1.78e-05	0.00125	CbGpPWpGaD
Zaleplon—AOX1—Disease—JUNB—kidney cancer	1.78e-05	0.00124	CbGpPWpGaD
Zaleplon—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—kidney cancer	1.77e-05	0.00124	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—MAPK1—kidney cancer	1.76e-05	0.00123	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GLIPR1—kidney cancer	1.74e-05	0.00122	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PPAT—kidney cancer	1.74e-05	0.00122	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—SCARB1—kidney cancer	1.71e-05	0.0012	CbGpPWpGaD
Zaleplon—GABRA1—Transmission across Chemical Synapses—RAF1—kidney cancer	1.69e-05	0.00119	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PTGS1—kidney cancer	1.69e-05	0.00118	CbGpPWpGaD
Zaleplon—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.66e-05	0.00116	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PSMD7—kidney cancer	1.66e-05	0.00116	CbGpPWpGaD
Zaleplon—GABRB2—Neuronal System—RAF1—kidney cancer	1.62e-05	0.00114	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—APRT—kidney cancer	1.62e-05	0.00113	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—FH—kidney cancer	1.62e-05	0.00113	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.62e-05	0.00113	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTT1—kidney cancer	1.59e-05	0.00111	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—VEGFA—kidney cancer	1.57e-05	0.0011	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—BCHE—kidney cancer	1.57e-05	0.0011	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.56e-05	0.00109	CbGpPWpGaD
Zaleplon—GABRA1—Neuronal System—BRAF—kidney cancer	1.55e-05	0.00109	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—SLC5A5—kidney cancer	1.55e-05	0.00109	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PDHB—kidney cancer	1.55e-05	0.00108	CbGpPWpGaD
Zaleplon—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—kidney cancer	1.55e-05	0.00108	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.54e-05	0.00108	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—POMC—kidney cancer	1.54e-05	0.00108	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GPC3—kidney cancer	1.52e-05	0.00107	CbGpPWpGaD
Zaleplon—GABRA2—Neuronal System—RAF1—kidney cancer	1.52e-05	0.00107	CbGpPWpGaD
Zaleplon—GABRB3—Neuronal System—RAF1—kidney cancer	1.51e-05	0.00106	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—SLC2A1—kidney cancer	1.5e-05	0.00105	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—PTGS1—kidney cancer	1.49e-05	0.00104	CbGpPWpGaD
Zaleplon—GABRG2—Neuronal System—RAF1—kidney cancer	1.48e-05	0.00104	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—CA2—kidney cancer	1.48e-05	0.00104	CbGpPWpGaD
Zaleplon—GABRB2—Transmission across Chemical Synapses—MAPK1—kidney cancer	1.45e-05	0.00102	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—CCBL1—kidney cancer	1.45e-05	0.00102	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.45e-05	0.00101	CbGpPWpGaD
Zaleplon—AOX1—Disease—CDKN2B—kidney cancer	1.45e-05	0.00101	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ALAD—kidney cancer	1.44e-05	0.00101	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.44e-05	0.00101	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.41e-05	0.000988	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ST3GAL2—kidney cancer	1.41e-05	0.000987	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ALDH1A1—kidney cancer	1.38e-05	0.000965	CbGpPWpGaD
Zaleplon—GABRA2—Transmission across Chemical Synapses—MAPK1—kidney cancer	1.36e-05	0.000954	CbGpPWpGaD
Zaleplon—GABRB3—Transmission across Chemical Synapses—MAPK1—kidney cancer	1.35e-05	0.000948	CbGpPWpGaD
Zaleplon—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.35e-05	0.000944	CbGpPWpGaD
Zaleplon—GABRG2—Transmission across Chemical Synapses—MAPK1—kidney cancer	1.33e-05	0.000931	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PGK1—kidney cancer	1.32e-05	0.000925	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—SLC5A3—kidney cancer	1.32e-05	0.000925	CbGpPWpGaD
Zaleplon—GABRA1—Neuronal System—RAF1—kidney cancer	1.3e-05	0.000909	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—LDHB—kidney cancer	1.3e-05	0.000907	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GLIPR1—kidney cancer	1.26e-05	0.000882	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PPAT—kidney cancer	1.26e-05	0.000882	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTP1—kidney cancer	1.25e-05	0.000875	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.23e-05	0.000864	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—ABCB1—kidney cancer	1.18e-05	0.000828	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—APRT—kidney cancer	1.17e-05	0.00082	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—FH—kidney cancer	1.17e-05	0.00082	CbGpPWpGaD
Zaleplon—GABRA1—Transmission across Chemical Synapses—MAPK1—kidney cancer	1.16e-05	0.000814	CbGpPWpGaD
Zaleplon—AOX1—Disease—HIF1A—kidney cancer	1.16e-05	0.000809	CbGpPWpGaD
Zaleplon—AOX1—Disease—TSC2—kidney cancer	1.15e-05	0.000807	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTM1—kidney cancer	1.15e-05	0.000804	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—CA9—kidney cancer	1.12e-05	0.000787	CbGpPWpGaD
Zaleplon—GABRB2—Neuronal System—MAPK1—kidney cancer	1.11e-05	0.00078	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTP1—kidney cancer	1.1e-05	0.000772	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GPC3—kidney cancer	1.1e-05	0.000771	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—CYP1A1—kidney cancer	1.09e-05	0.000762	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	1.09e-05	0.000762	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—CA2—kidney cancer	1.07e-05	0.00075	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ALAD—kidney cancer	1.04e-05	0.000731	CbGpPWpGaD
Zaleplon—GABRA2—Neuronal System—MAPK1—kidney cancer	1.04e-05	0.000731	CbGpPWpGaD
Zaleplon—GABRB3—Neuronal System—MAPK1—kidney cancer	1.04e-05	0.000726	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ST3GAL2—kidney cancer	1.02e-05	0.000714	CbGpPWpGaD
Zaleplon—GABRG2—Neuronal System—MAPK1—kidney cancer	1.02e-05	0.000713	CbGpPWpGaD
Zaleplon—AOX1—Disease—APC—kidney cancer	1.02e-05	0.000713	CbGpPWpGaD
Zaleplon—AOX1—Disease—KIT—kidney cancer	1.02e-05	0.000713	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTM1—kidney cancer	1.01e-05	0.00071	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	1e-05	0.0007	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ALDH1A1—kidney cancer	9.96e-06	0.000698	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	9.61e-06	0.000673	CbGpPWpGaD
Zaleplon—AOX1—Disease—BRAF—kidney cancer	9.57e-06	0.00067	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—CRABP1—kidney cancer	9.55e-06	0.000669	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—SLC5A3—kidney cancer	9.55e-06	0.000669	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PGK1—kidney cancer	9.55e-06	0.000669	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	9.48e-06	0.000664	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—LDHB—kidney cancer	9.36e-06	0.000656	CbGpPWpGaD
Zaleplon—GABRA1—Neuronal System—MAPK1—kidney cancer	8.9e-06	0.000623	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ITPR2—kidney cancer	8.88e-06	0.000622	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—RAF1—kidney cancer	8.73e-06	0.000611	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ACY1—kidney cancer	8.45e-06	0.000592	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—RAF1—kidney cancer	8.18e-06	0.000573	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—RAF1—kidney cancer	8.13e-06	0.000569	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—CA9—kidney cancer	8.12e-06	0.000569	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—POMC—kidney cancer	8.12e-06	0.000568	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ACHE—kidney cancer	8.1e-06	0.000567	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTT1—kidney cancer	8.1e-06	0.000567	CbGpPWpGaD
Zaleplon—AOX1—Disease—RAF1—kidney cancer	7.99e-06	0.00056	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—RAF1—kidney cancer	7.98e-06	0.000559	CbGpPWpGaD
Zaleplon—AOX1—Disease—ERBB2—kidney cancer	7.91e-06	0.000554	CbGpPWpGaD
Zaleplon—AOX1—Disease—MTOR—kidney cancer	7.8e-06	0.000546	CbGpPWpGaD
Zaleplon—AOX1—Disease—CD4—kidney cancer	7.79e-06	0.000545	CbGpPWpGaD
Zaleplon—AOX1—Disease—PTGS2—kidney cancer	7.73e-06	0.000541	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—SCARB1—kidney cancer	7.66e-06	0.000537	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PTGS1—kidney cancer	7.59e-06	0.000531	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PSMD7—kidney cancer	7.44e-06	0.000521	CbGpPWpGaD
Zaleplon—AOX1—Disease—CDKN1B—kidney cancer	7.32e-06	0.000513	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PDHB—kidney cancer	7.19e-06	0.000503	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—POMC—kidney cancer	7.16e-06	0.000502	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—BCHE—kidney cancer	7.05e-06	0.000494	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—RAF1—kidney cancer	6.98e-06	0.000489	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—SLC5A5—kidney cancer	6.97e-06	0.000488	CbGpPWpGaD
Zaleplon—AOX1—Disease—CTNNB1—kidney cancer	6.92e-06	0.000484	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—CRABP1—kidney cancer	6.9e-06	0.000483	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—CCBL1—kidney cancer	6.76e-06	0.000473	CbGpPWpGaD
Zaleplon—AOX1—Disease—PTEN—kidney cancer	6.74e-06	0.000472	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—SLC2A1—kidney cancer	6.73e-06	0.000471	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PTGS2—kidney cancer	6.47e-06	0.000453	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ITPR2—kidney cancer	6.42e-06	0.000449	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PPAT—kidney cancer	5.86e-06	0.00041	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GLIPR1—kidney cancer	5.86e-06	0.00041	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTT1—kidney cancer	5.85e-06	0.00041	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ACHE—kidney cancer	5.85e-06	0.00041	CbGpPWpGaD
Zaleplon—AOX1—Disease—MAPK3—kidney cancer	5.76e-06	0.000403	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PTEN—kidney cancer	5.65e-06	0.000395	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTP1—kidney cancer	5.61e-06	0.000393	CbGpPWpGaD
Zaleplon—AOX1—Disease—MYC—kidney cancer	5.6e-06	0.000392	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—SCARB1—kidney cancer	5.54e-06	0.000388	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PTGS1—kidney cancer	5.48e-06	0.000384	CbGpPWpGaD
Zaleplon—AOX1—Disease—MAPK1—kidney cancer	5.48e-06	0.000384	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—FH—kidney cancer	5.45e-06	0.000381	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—APRT—kidney cancer	5.45e-06	0.000381	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PSMD7—kidney cancer	5.38e-06	0.000377	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ABCB1—kidney cancer	5.31e-06	0.000372	CbGpPWpGaD
Zaleplon—AOX1—Disease—KRAS—kidney cancer	5.18e-06	0.000363	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTM1—kidney cancer	5.16e-06	0.000361	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GPC3—kidney cancer	5.12e-06	0.000359	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—BCHE—kidney cancer	5.1e-06	0.000357	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—SLC5A5—kidney cancer	5.04e-06	0.000353	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—CA2—kidney cancer	4.98e-06	0.000349	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—CYP1A1—kidney cancer	4.89e-06	0.000342	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—SLC2A1—kidney cancer	4.86e-06	0.000341	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ALAD—kidney cancer	4.85e-06	0.00034	CbGpPWpGaD
Zaleplon—AOX1—Disease—PIK3CA—kidney cancer	4.76e-06	0.000333	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ST3GAL2—kidney cancer	4.74e-06	0.000332	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ALDH1A1—kidney cancer	4.63e-06	0.000324	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PGK1—kidney cancer	4.44e-06	0.000311	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—SLC5A3—kidney cancer	4.44e-06	0.000311	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—LDHB—kidney cancer	4.35e-06	0.000305	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTP1—kidney cancer	4.06e-06	0.000284	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PIK3CA—kidney cancer	3.98e-06	0.000279	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ABCB1—kidney cancer	3.84e-06	0.000269	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—CA9—kidney cancer	3.77e-06	0.000264	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTM1—kidney cancer	3.73e-06	0.000261	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—POMC—kidney cancer	3.65e-06	0.000255	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—CYP1A1—kidney cancer	3.53e-06	0.000247	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—CRABP1—kidney cancer	3.21e-06	0.000225	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ITPR2—kidney cancer	2.98e-06	0.000209	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PTGS2—kidney cancer	2.91e-06	0.000204	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTT1—kidney cancer	2.72e-06	0.000191	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ACHE—kidney cancer	2.72e-06	0.000191	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—POMC—kidney cancer	2.63e-06	0.000185	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—SCARB1—kidney cancer	2.58e-06	0.00018	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PTGS1—kidney cancer	2.55e-06	0.000179	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PTEN—kidney cancer	2.54e-06	0.000178	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PSMD7—kidney cancer	2.5e-06	0.000175	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—BCHE—kidney cancer	2.37e-06	0.000166	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.34e-06	0.000164	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.26e-06	0.000158	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PTGS2—kidney cancer	2.1e-06	0.000147	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTP1—kidney cancer	1.89e-06	0.000132	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PTEN—kidney cancer	1.83e-06	0.000128	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PIK3CA—kidney cancer	1.79e-06	0.000125	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ABCB1—kidney cancer	1.79e-06	0.000125	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTM1—kidney cancer	1.73e-06	0.000121	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.64e-06	0.000115	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.29e-06	9.06e-05	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—POMC—kidney cancer	1.23e-06	8.58e-05	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PTGS2—kidney cancer	9.77e-07	6.84e-05	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PTEN—kidney cancer	8.52e-07	5.97e-05	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.01e-07	4.21e-05	CbGpPWpGaD
